Vaxcyte, Inc. PCVX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s operating lease right-of-use asset amortization?
- Vaxcyte, Inc. (PCVX) reported operating lease right-of-use asset amortization of $2.91M in Q1 2026.
- How has Vaxcyte, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- Vaxcyte, Inc.'s operating lease right-of-use asset amortization increased by 51.6% year-over-year, from $1.92M to $2.91M.
- What is the long-term trend for Vaxcyte, Inc.'s operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s operating lease right-of-use asset amortization has grown at a 50.3% compound annual growth rate (CAGR), from $1.66M to $8.46M.